Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism
Status:
RECRUITING
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the safety and efficacy of a novel PTH replacement therapy drug in patients with hypoparathyroidism. The drug is an mRNA drug which will be translated into PTH after intravenous administration, to achieve the therapeutic effect.